(S (NP-SBJ-65 (NP Ras/NN oncogene/NN transformation/NN) (PP of/IN (NP human/JJ B/NN lymphoblasts/NNS))) (VP is/VBZ (VP associated/VBN (NP *-65/-NONE-) (PP-COOD (PP with/IN (NP lymphocyte/NN activation/NN)) and/CC (PP with/IN (NP (NP a/DT block/NN) (PP of/IN (NP differentiation/NN))))))) ./.)
(S (NP-SBJ The/DT p21ras/NN small/JJ GTP/NN binding/NN proteins/NNS) (VP-COOD (VP participate/VBP (PP in/IN (NP (NP signal/JJ transduction/NN) (PP from/IN (NP cell/NN surface/NN receptors/NNS))))) and/CC (VP affect/VB (NP (NP neoplastic/JJ (NP-COOD (NP transformation/NN) and/CC (NP development/NN))) (PP in/IN (NP many/JJ different/JJ cell/NN types/NNS))))) ./.)
(S (PP In/IN (NP the/DT present/JJ study/NN)) ,/, (NP-SBJ we/PRP) (VP examined/VBD (NP (NP the/DT relationship/NN) (PP between/IN (NP (NP ras/NN (NP-COOD (NP transformation/NN) and/CC (NP differentiation/NN))) (PP of/IN (NP human/JJ B/NN lymphocytes/NNS)))))) ./.)
(S (NP-SBJ We/PRP) (VP show/VBP (SBAR that/IN (S (NP-SBJ-66 (NP the/DT constitutive/JJ expression/NN) (PP of/IN (NP the/DT T24/NN Ha-ras/NN oncogene/NN)) (PP in/IN (NP EBV-immortalized/JJ B/NN lymphoblasts/NNS))) (VP was/VBD (VP associated/VBN (NP *-66/-NONE-) (PP with/IN (NP (NP the/DT induction/NN) (PP of/IN (NP the/DT interleukin/NN 2/CD receptor/NN alpha/NN subunit/NN)))) ,/, (PP with/IN (NP-COOD (NP an/DT impaired/JJ immunoglobulin/NN gene/NN expression/NN) ,/, (NP altered/JJ adhesion/NN properties/NNS) and/CC (NP (NP increased/VBN survival/NN) (PP in/IN (NP serum-free/JJ medium/NN)))))))))) ./.)
(S (SBAR Since/IN (S (NP-SBJ (NP induction/NN) (PP of/IN (NP the/DT IL-2/NN receptor/NN alpha/NN subunit/NN))) (VP is/VBZ (NP-PRD (NP a/DT hallmark/NN) (PP of/IN (NP lymphocyte/NN activation/NN)))))) ,/, (NP-SBJ we/PRP) (VP suggest/VBP (SBAR that/IN (S (NP-SBJ p21ras/NN) (ADVP naturally/RB) (VP triggers/VBZ (NP B/NN cell/NN activation/NN))))) ./.)
(S (S (NP-SBJ The/DT ras-transformed/JJ lymphocytes/NNS) (VP displayed/VBD (NP a/DT (ADJP fully/RB functional/JJ) IL-2r/NN) ,/, (SBAR as/IN (S (NP-SBJ-67 */-NONE-) (VP assessed/VBN (NP *-67/-NONE-) (PP by/IN (NP (NP c-fos/NN induction/NN) (PP-TMP following/VBG (NP (NP treatment/NN) (PP with/IN (NP IL-2/NN))))))))))) ;/: (S (ADVP nevertheless/RB) ,/, (NP-SBJ they/PRP) (VP were/VBD not/RB (NP-PRD (NP growth/NN) (VP stimulated/VBN (NP */-NONE-) (PP by/IN (NP this/DT lymphokine/NN)))))) ./.)
(S (NP-SBJ (NP The/DT decreased/VBN expression/NN) (PP of/IN (NP immunoglobulin/NN genes/NNS))) (VP indicates/VBZ (SBAR that/IN (S (NP-SBJ-68 the/DT ras/NN oncogene/NN) (VP blocks/VBZ (NP (NP terminal/JJ differentiation/NN) (PP to/TO (NP plasma/NN cells/NNS))) ,/, (PP (ADVP possibly/RB) by/IN (S (NP-SBJ *-68/-NONE-) (VP inhibiting/VBG (NP (NP the/DT activity/NN) (PP of/IN (NP lymphocyte-specific/JJ transcription/NN factors/NNS)))))))))) ./.)
(S (ADVP Somewhat/RB unexpectedly/RB) ,/, (NP-SBJ the/DT constitutive/JJ p21ras/NN activity/NN) (VP did/VBD not/RB (VP cause/VB (NP (NP an/DT increased/VBN DNA/NN binding/NN) (PP of/IN (NP transcription/NN factors/NNS (NP-COOD (NP (NP PEA1/NN) (PRN -LRB-/-LRB- (NP AP1/NN) -RRB-/-RRB-)) ,/, (NP PEA3/NN) ,/, (NP Oct-2/NN) or/CC (NP NF-kB/NN))))))) ./.)
